Advances in biomarkers of resistance to KRAS mutation-targeted inhibitors
Abstract KRAS mutations represent the most common driver genetic alterations in multiple malignant tumors, particularly exerting well-defined oncogenic driver roles in non-small cell lung cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. The recent success of KRAS G12C mutation-specif...
Zapisane w:
| Główni autorzy: | , , , |
|---|---|
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
Springer
2025-10-01
|
| Seria: | Discover Oncology |
| Hasła przedmiotowe: | |
| Dostęp online: | https://doi.org/10.1007/s12672-025-03569-x |
| Etykiety: |
Nie ma etykietki, Dołącz pierwszą etykiete!
|